What is DermTech?
DermTech, Inc. is a molecular diagnostic company focused on the development and commercialization of innovative non-invasive genomics tests designed to aid in the diagnosis and management of melanoma within the United States. The company's proprietary technology aims to provide accurate and accessible diagnostic tools, addressing a critical need in dermatological care. By leveraging advanced genomic insights, DermTech seeks to improve patient outcomes and streamline the diagnostic process for healthcare providers.
How much funding has DermTech raised?
DermTech has raised a total of $87.4M across 4 funding rounds:
Other Financing Round
$10M
Other Financing Round
$2.4M
Series C
$10M
Share Placement
$65M
Other Financing Round (2007): $10M with participation from Gene Salkind and Gary Jacobs
Other Financing Round (2015): $2.4M led by Undisclosed
Series C (2017): $10M supported by RTW Investments
Share Placement (2020): $65M featuring Undisclosed
Key Investors in DermTech
RTW Investments
RTW Investments is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, from company creation to public companies. The firm partners with companies at various stages of development, providing not just capital but also expertise to support their success. RTW aims to identify and develop transformative companies that significantly improve patients' lives, leveraging deep scientific knowledge and a long-term investment approach. Their mission extends beyond financial gain, as they strive to create a greater impact in science and medicine for the benefit of patients worldwide.
What's next for DermTech?
With the recent infusion of major strategic capital, DermTech is poised for accelerated growth and expansion of its diagnostic offerings. The company's focus on non-invasive melanoma diagnostics positions it to capitalize on the increasing demand for advanced molecular testing in healthcare. Future developments are likely to involve further refinement of its genomic platforms, broader market penetration, and potential exploration of new diagnostic applications. This strategic investment will be instrumental in supporting research and development, enhancing commercialization efforts, and solidifying DermTech's market position in the competitive landscape of molecular diagnostics.
See full DermTech company page
